Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial
To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively ti...
Gespeichert in:
Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2013-06, Vol.65 (6), p.1430 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 6 |
container_start_page | 1430 |
container_title | Arthritis & rheumatology (Hoboken, N.J.) |
container_volume | 65 |
creator | Navarro-Millán, Iris Charles-Schoeman, Christina Yang, Shuo Bathon, Joan M Bridges, Jr, S Louis Chen, Lang Cofield, Stacey S Dell'Italia, Louis J Moreland, Larry W O'Dell, James R Paulus, Harold E Curtis, Jeffrey R |
description | To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy.
This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks.
At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02).
Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined. |
doi_str_mv | 10.1002/art.37916 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1356997567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2984246941</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-d7a20aadbff4b1deae05e72a2bba7291eb5d4d9c6e40d675b5b56d5b34ed86c53</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozvhY-Ack4LqaR5NadzL4AsGNroebya3N0DY1SdH5Sf5LMzhu5S4uXL5z7uEQcsbZJWdMXEFIl7Kqud4jc65EXTAu-T6ZCyl0oXjNZ-QoxjXLrFTykMyELDVjVTkn34sWhneM1A20c6Mfg0_ohkghRr9ykNDST5da2mNqfQr4lU_UB7ryvXEDJOcHmloMMG62Hgih29DQ4tRD8s7SnK0NLrl4QwPGqUuRNsH3Ww3NdpB6HBL1zT_KzDnoTshBA13E090-Jm_3d6-Lx-L55eFpcftcjELWqbAVCAZgTdOUhlsEZAorAcIYqETN0Shb2nqlsWRWV8rk0VYZWaK91islj8nFr2-u4mPCmJZrP4Uhv1xyqXRdV0pXmTrfUZPp0S7H4HoIm-Vfs_IH8OGAeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356997567</pqid></control><display><type>article</type><title>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M ; Bridges, Jr, S Louis ; Chen, Lang ; Cofield, Stacey S ; Dell'Italia, Louis J ; Moreland, Larry W ; O'Dell, James R ; Paulus, Harold E ; Curtis, Jeffrey R</creator><creatorcontrib>Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M ; Bridges, Jr, S Louis ; Chen, Lang ; Cofield, Stacey S ; Dell'Italia, Louis J ; Moreland, Larry W ; O'Dell, James R ; Paulus, Harold E ; Curtis, Jeffrey R</creatorcontrib><description>To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy.
This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks.
At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02).
Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 1529-0131</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.37916</identifier><identifier>PMID: 23460074</identifier><identifier>CODEN: ARHEAW</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject><![CDATA[Adult ; Aged ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Cholesterol ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Drug therapy ; Drug Therapy, Combination ; Etanercept ; Female ; Humans ; Hydroxychloroquine - administration & dosage ; Hydroxychloroquine - therapeutic use ; Immunoglobulin G - administration & dosage ; Immunoglobulin G - therapeutic use ; Male ; Methotrexate ; Methotrexate - administration & dosage ; Methotrexate - therapeutic use ; Middle Aged ; Receptors, Tumor Necrosis Factor - administration & dosage ; Receptors, Tumor Necrosis Factor - therapeutic use ; Sulfasalazine - administration & dosage ; Sulfasalazine - therapeutic use ; Treatment Outcome]]></subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2013-06, Vol.65 (6), p.1430</ispartof><rights>Copyright © 2013 by the American College of Rheumatology.</rights><rights>Copyright © 2013 by the American College of Rheumatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23460074$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Navarro-Millán, Iris</creatorcontrib><creatorcontrib>Charles-Schoeman, Christina</creatorcontrib><creatorcontrib>Yang, Shuo</creatorcontrib><creatorcontrib>Bathon, Joan M</creatorcontrib><creatorcontrib>Bridges, Jr, S Louis</creatorcontrib><creatorcontrib>Chen, Lang</creatorcontrib><creatorcontrib>Cofield, Stacey S</creatorcontrib><creatorcontrib>Dell'Italia, Louis J</creatorcontrib><creatorcontrib>Moreland, Larry W</creatorcontrib><creatorcontrib>O'Dell, James R</creatorcontrib><creatorcontrib>Paulus, Harold E</creatorcontrib><creatorcontrib>Curtis, Jeffrey R</creatorcontrib><title>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheum</addtitle><description>To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy.
This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks.
At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02).
Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.</description><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Cholesterol</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Etanercept</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxychloroquine - administration & dosage</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Immunoglobulin G - administration & dosage</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Male</subject><subject>Methotrexate</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Receptors, Tumor Necrosis Factor - administration & dosage</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Sulfasalazine - administration & dosage</subject><subject>Sulfasalazine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>2326-5191</issn><issn>1529-0131</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxDAUhYMozvhY-Ack4LqaR5NadzL4AsGNroebya3N0DY1SdH5Sf5LMzhu5S4uXL5z7uEQcsbZJWdMXEFIl7Kqud4jc65EXTAu-T6ZCyl0oXjNZ-QoxjXLrFTykMyELDVjVTkn34sWhneM1A20c6Mfg0_ohkghRr9ykNDST5da2mNqfQr4lU_UB7ryvXEDJOcHmloMMG62Hgih29DQ4tRD8s7SnK0NLrl4QwPGqUuRNsH3Ww3NdpB6HBL1zT_KzDnoTshBA13E090-Jm_3d6-Lx-L55eFpcftcjELWqbAVCAZgTdOUhlsEZAorAcIYqETN0Shb2nqlsWRWV8rk0VYZWaK91islj8nFr2-u4mPCmJZrP4Uhv1xyqXRdV0pXmTrfUZPp0S7H4HoIm-Vfs_IH8OGAeg</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Navarro-Millán, Iris</creator><creator>Charles-Schoeman, Christina</creator><creator>Yang, Shuo</creator><creator>Bathon, Joan M</creator><creator>Bridges, Jr, S Louis</creator><creator>Chen, Lang</creator><creator>Cofield, Stacey S</creator><creator>Dell'Italia, Louis J</creator><creator>Moreland, Larry W</creator><creator>O'Dell, James R</creator><creator>Paulus, Harold E</creator><creator>Curtis, Jeffrey R</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20130601</creationdate><title>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</title><author>Navarro-Millán, Iris ; Charles-Schoeman, Christina ; Yang, Shuo ; Bathon, Joan M ; Bridges, Jr, S Louis ; Chen, Lang ; Cofield, Stacey S ; Dell'Italia, Louis J ; Moreland, Larry W ; O'Dell, James R ; Paulus, Harold E ; Curtis, Jeffrey R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-d7a20aadbff4b1deae05e72a2bba7291eb5d4d9c6e40d675b5b56d5b34ed86c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Cholesterol</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Etanercept</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxychloroquine - administration & dosage</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Immunoglobulin G - administration & dosage</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Male</topic><topic>Methotrexate</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Receptors, Tumor Necrosis Factor - administration & dosage</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Sulfasalazine - administration & dosage</topic><topic>Sulfasalazine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Navarro-Millán, Iris</creatorcontrib><creatorcontrib>Charles-Schoeman, Christina</creatorcontrib><creatorcontrib>Yang, Shuo</creatorcontrib><creatorcontrib>Bathon, Joan M</creatorcontrib><creatorcontrib>Bridges, Jr, S Louis</creatorcontrib><creatorcontrib>Chen, Lang</creatorcontrib><creatorcontrib>Cofield, Stacey S</creatorcontrib><creatorcontrib>Dell'Italia, Louis J</creatorcontrib><creatorcontrib>Moreland, Larry W</creatorcontrib><creatorcontrib>O'Dell, James R</creatorcontrib><creatorcontrib>Paulus, Harold E</creatorcontrib><creatorcontrib>Curtis, Jeffrey R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Navarro-Millán, Iris</au><au>Charles-Schoeman, Christina</au><au>Yang, Shuo</au><au>Bathon, Joan M</au><au>Bridges, Jr, S Louis</au><au>Chen, Lang</au><au>Cofield, Stacey S</au><au>Dell'Italia, Louis J</au><au>Moreland, Larry W</au><au>O'Dell, James R</au><au>Paulus, Harold E</au><au>Curtis, Jeffrey R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheum</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>65</volume><issue>6</issue><spage>1430</spage><pages>1430-</pages><issn>2326-5191</issn><eissn>1529-0131</eissn><eissn>2326-5205</eissn><coden>ARHEAW</coden><abstract>To study changes in lipid profiles at 24 weeks among patients with early rheumatoid arthritis (RA) participating in the Treatment of Early RA (TEAR) trial and randomized to receive methotrexate (MTX) plus etanercept, triple therapy (MTX plus sulfasalazine plus hydroxychloroquine), or aggressively titrated MTX monotherapy.
This TEAR substudy included 459 participants with biologic specimens. Serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were measured at 0 and 24 weeks.
At 24 weeks, there were statistically significant increases in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms. The observed increases were 31.4 mg/dl, 28.7 mg/dl, and 30 mg/dl in LDL cholesterol, 19.3 mg/dl, 22.3 mg/dl, and 20.6 mg/dl in HDL cholesterol, and 56.8 mg/dl, 53 mg/dl, and 57.3 mg/dl in total cholesterol (P < 0.0001 versus baseline for each comparison). There was a statistically significant decrease in the ratio of total cholesterol to HDL cholesterol at 24 weeks in all 3 treatment groups versus baseline. There was no difference in any lipid changes between the 3 treatment arms. After multivariable adjustment, change in C-reactive protein, but not the Disease Activity Score in 28 joints, was associated with change in LDL cholesterol (P = 0.03) and total cholesterol (P = 0.01). Baseline glucocorticoid use was associated with changes in HDL cholesterol (P = 0.03) and total cholesterol (P = 0.02).
Levels of total cholesterol, LDL cholesterol, and HDL cholesterol increased comparably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among patients with early RA with active disease participating in a clinical trial. The clinical relevance of short-term changes in traditional lipids on cardiovascular outcomes remains to be determined.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>23460074</pmid><doi>10.1002/art.37916</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2326-5191 |
ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2013-06, Vol.65 (6), p.1430 |
issn | 2326-5191 1529-0131 2326-5205 |
language | eng |
recordid | cdi_proquest_journals_1356997567 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adult Aged Antirheumatic Agents - administration & dosage Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Cholesterol Cholesterol, HDL - blood Cholesterol, LDL - blood Drug therapy Drug Therapy, Combination Etanercept Female Humans Hydroxychloroquine - administration & dosage Hydroxychloroquine - therapeutic use Immunoglobulin G - administration & dosage Immunoglobulin G - therapeutic use Male Methotrexate Methotrexate - administration & dosage Methotrexate - therapeutic use Middle Aged Receptors, Tumor Necrosis Factor - administration & dosage Receptors, Tumor Necrosis Factor - therapeutic use Sulfasalazine - administration & dosage Sulfasalazine - therapeutic use Treatment Outcome |
title | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A57%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20lipoproteins%20associated%20with%20methotrexate%20or%20combination%20therapy%20in%20early%20rheumatoid%20arthritis:%20results%20from%20the%20treatment%20of%20early%20rheumatoid%20arthritis%20trial&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Navarro-Mill%C3%A1n,%20Iris&rft.date=2013-06-01&rft.volume=65&rft.issue=6&rft.spage=1430&rft.pages=1430-&rft.issn=2326-5191&rft.eissn=1529-0131&rft.coden=ARHEAW&rft_id=info:doi/10.1002/art.37916&rft_dat=%3Cproquest_pubme%3E2984246941%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356997567&rft_id=info:pmid/23460074&rfr_iscdi=true |